Drissi Hicham, Paglia David N, Alaee Farhang, Yoshida Ryu
New England Musculoskeletal Institute and Department of Orthopaedic Surgery.
Genes Dis. 2014 Dec 1;1(2):140-148. doi: 10.1016/j.gendis.2014.07.006.
The multifaceted sequence of events that follow fracture repair can be further complicated when considering risk factors for impaired union, present in a large and growing percentage of the population. Risk factors such as diabetes, substance abuse, and poor nutrition affect both the young and old alike, and have been shown to dramatically impair the body's natural healing processes. To this end, biotherapeudic interventions such as ultrasound, electrical simulation, growth factor treatment (BMP-2, BMP-7, PDGF-BB, FGF-2) have been evaluated in preclinical models and in some cases are used widely for patients with established non-union or risk/indication or impaired healing (ie. ultrasound, BMP-2, etc.). Despite the promise of these interventions, they have been shown to be reliant on patient compliance and can produce adverse side-effects such as heterotopic ossification. Gene and cell therapy approaches have attempted to apply controlled regimens of these factors and have produced promising results. However, there are safety and efficacy concerns that may limit the translation of these approaches. In addition, none of the above mentioned approaches consider genetic variation between individual patients. Several clinical and preclinical studies have demonstrated a genetic component to fracture repair and that SNPs and genetic background variation play major roles in the determination of healing outcomes. Despite this, there is a need for preclinical data to dissect the mechanism underlying the influence of specific gene loci on the processes of fracture healing, which will be paramount in the future of patient-centered interventions for fracture repair.
当考虑到骨折愈合受损的风险因素时,骨折修复后多方面的一系列事件可能会进一步复杂化,这些风险因素在越来越多的人群中存在。糖尿病、药物滥用和营养不良等风险因素对年轻人和老年人都有影响,并且已被证明会显著损害身体的自然愈合过程。为此,诸如超声、电刺激、生长因子治疗(骨形态发生蛋白-2、骨形态发生蛋白-7、血小板衍生生长因子-BB、成纤维细胞生长因子-2)等生物治疗干预措施已在临床前模型中得到评估,并且在某些情况下被广泛用于已确诊骨不连或有愈合风险/指征或愈合受损的患者(如超声、骨形态发生蛋白-2等)。尽管这些干预措施前景广阔,但已证明它们依赖于患者的依从性,并且可能产生诸如异位骨化等不良副作用。基因和细胞治疗方法试图应用这些因子的可控方案,并已取得了有前景的结果。然而,存在一些安全和有效性方面的担忧,可能会限制这些方法的转化应用。此外,上述方法均未考虑个体患者之间的基因差异。多项临床和临床前研究已证明骨折修复存在遗传因素,单核苷酸多态性和遗传背景变异在愈合结果的决定中起主要作用。尽管如此,仍需要临床前数据来剖析特定基因位点对骨折愈合过程影响的潜在机制,这在以患者为中心的骨折修复干预措施的未来发展中将至关重要。